Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
What's Your Reaction?
